Efflux pumps are widely implicated in antibiotic resistance because they can extrude the majority of clinically relevant antibiotics from within cells to the extracellular environment. However, there is increasing evidence from many studies to suggest that the pumps also play a role in biofilm formation. These studies have involved investigating the effects of efflux pump gene mutagenesis and efflux pump inhibitors on biofilm formation, and measuring the levels of efflux pump gene expression in biofilms. In particular, several key pathogenic species associated with increasing multidrug resistance, such as Acinetobacter baumannii, Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus, have been investigated, whilst other studies have focused on Salmonella enterica serovar Typhimurium as a model organism and problematic pathogen. Studies have shown that efflux pumps, including AcrAB-TolC of E. coli, MexAB-OprM of P. aeruginosa, AdeFGH of A. baumannii and AcrD of S. enterica, play important roles in biofilm formation. The substrates for such pumps, and whether changes in their efflux activity affect biofilm formation directly or indirectly, remain to be determined. By understanding the roles that efflux pumps play in biofilm formation, novel therapeutic strategies can be developed to inhibit their function, to help disrupt biofilms and improve the treatment of infections. This review will discuss and evaluate the evidence for the roles of efflux pumps in biofilm formation and the potential approaches to overcome the increasing problem of biofilm-based infections.
Introduction
Antibiotic resistance is one of the biggest threats to global public health, food security and development today. As a result of increasing resistance, the number of clinically efficacious antibiotics available for the treatment of infections caused by MDR bacteria has been dwindling at a concerning rate over the last few decades. Furthermore, there is a significant void in the antibiotic discovery timeline: no new classes of antibiotics have been discovered since lipopeptides in 1987. 1 The reason for the discovery void stems from several different factors, including the withdrawal of pharmaceutical companies from antibacterial research, due to poor economic incentives as well as the regulatory barriers companies face getting novel antibiotics approved for clinical use. 2 The recommendations of the recent Antimicrobial Resistance Review aim to address some of the deficiencies of the economic model to restimulate the development of new antibiotics. 3 
Antibiotic resistance
Antibiotic resistance is an ancient and natural phenomenon that has been observed in bacteria inhabiting a broad range of ecological niches, including isolated deep cave networks, forest soil and ocean floor sediment. 4 Although antibiotic resistance in bacteria is a natural occurrence, anthropogenic influences, such as antibiotic overuse, inappropriate prescribing and extensive agricultural use, have all contributed to the emergence and spread of MDR bacteria, which are resistant to many of the clinically relevant antibiotics. 5 Recently, the WHO published the first-ever list of 12 MDR pathogens that currently pose the greatest threat to human health and require the urgent development of novel antibiotics for their treatment. 6 Many of the organisms in which efflux pump function has been linked to alterations in biofilm formation are included on this list.
Bacteria can acquire or develop antibiotic resistance through spontaneous mutations in their chromosomal genes and by horizontal gene transfer (HGT). 7 Mechanisms of antibiotic resistance in bacteria include the following ( Figure 1 ): inactivation of the antibiotic through hydrolysis or modification, such as phosphorylation by an enzyme; alteration of the antibiotic target through genetic mutations or post-translational modification; overproduction of the antibiotic target through gene amplification; decreased influx/ penetration of the antibiotic into the cell, e.g. though changes in cell wall structure; and increased efflux of the antibiotic out of the cell through efflux pumps and porins. 7, 8 Whilst antibiotic resistance genes can be present in the bacterial chromosome, they are also present in mobile genetic elements, such as plasmids. 7 HGT can facilitate the transfer of plasmids that contain antibiotic resistance genes between the same or different species of bacteria, and can lead to the development and spread of MDR pathogens. 9 The problem of antibiotic resistance is further compounded by biofilms, which display significantly higher genotypic and phenotypic tolerance/resistance to antibiotics than planktonic cells.
Biofilms are collections of sessile microorganisms in which cells are frequently embedded within a self-produced matrix of extracellular polymeric substances (EPSs) that adhere to each other and/or to a surface; 11 biofilm microorganisms also exhibit altered phenotype with respect to growth rate and gene transcription. 12 The matrix EPSs include lipids, nucleic acids, polysaccharides and proteins; they play a role in maintaining the structural integrity of the biofilm, facilitating adhesion to surfaces and forming a network of cohesive polymers that ensure biofilm cells remain stationary. 13 Biofilm formation can be described in four stages ( Figure 2 ): (i) the planktonic cells reversibly attach to a suitable surface; (ii) the cells begin proliferating and irreversibly adhere to the surface to form microcolonies; (iii) the cells grow and mature from microcolonies into clusters of multilayered cells and begin to synthesize EPSs that comprise the matrix; and (iv) some of the cells within the biofilm detach and disperse as planktonic cells to form biofilms in other settings. 14 Bacteria form biofilms in response to various factors, including exposure to subinhibitory concentrations of antibiotics, nutritional and metabolic cues, and host-derived signals. 15 This mode of growth, in many cases, affords biofilm cells significantly greater protection against antibiotics and disinfectants than their planktonic counterparts through a range of different mechanisms, such as impermeability of the biofilm matrix to antibiotics, 16 decreased growth rate in the core of biofilms due to nutrient and oxygen gradients, 17 the presence of persister cells that tolerate antibiotics, 18 and increased expression of efflux pumps 19 within the biofilm. This is sometimes termed antibiotic or disinfectant tolerance or phenotypic resistance, to indicate that the increased survival is a function of the bacterial biofilm lifestyle rather than being due to specific genetic changes. 20 Biofilm formation has been observed in several different pathogenic species of bacteria in clinical, domestic and industrial environments. Biofilms have been found in clinical settings, including the surfaces of medical devices and living tissues, such as heart valves, lungs and tooth enamel. 21 Biofilm formation on medical devices is one of the major causes of nosocomial infections that can be difficult to treat due to the increased ability to tolerate antibiotics at much greater concentrations than their planktonic counterparts. Both the MIC and the MBC for sessile biofilm cells are often 10-1000 times higher than for planktonic cells. 22 Some species exhibit increased resistance to a diverse range of antibiotics; for instance, Pseudomonas aeruginosa biofilms display increased tolerance to b-lactams, chloramphenicol, quinolones and tetracycline. 23 Biofilms on medical devices can also increase the risk of dissemination to other sites within the body and trigger chronic infections in the patient. 24 As shown in Table 1 , numerous studies have reported that several important pathogenic species of bacteria can form biofilms on medical devices and cause biofilm infections, which are implicated in several human diseases.
The adoption and maintenance of a biofilm mode of growth by bacteria is regulated by quorum sensing (QS), which is a system of intercellular communication that involves signalling molecules to coordinate various bacterial behaviours and processes according to the cell population density. To understand the possible role of efflux pumps in biofilm formation and to relate this to antibiotic resistance mediated by biofilms, it is necessary to give an overview of the mechanisms of QS in both Gram-negative and Grampositive bacteria.
Quorum sensing
Quorum sensing (QS) is a process whereby bacteria synthesize, recognize and respond to extracellular signalling molecules known as autoinducers (AIs) to mediate intercellular communication. Bacteria utilize the concentration of AIs in their environment to monitor changes in their cell numbers and to coordinate the expression of quorum-specific genes. These genes are involved in various bacterial behaviours, including antibiotic production, biofilm formation, bioluminescence, genetic competence, sporulation and virulence. 35 QS can occur both within and between bacterial species, and between bacteria and other microbes, and is crucial for the survival of bacteria in a wide range of environments. 36 There are differences in the type of AIs used, the signal relay mechanisms and the identity of quorum-specific genes between different species of bacteria; however, all QS systems depend on three essential principles: synthesis of AIs, detection of AIs by receptors and activation of quorum-specific genes by transcription factors. Most bacteria that participate in QS constitutively synthesize AIs, which are the extracellular signalling molecules, although there are some bacteria that possess receptors but no synthetic Review machinery. During periods of low population density, AIs diffuse away and their concentration remains below the threshold required for detection. An elevation in the population density causes there to be many cells in close proximity synthesizing AIs, which results in an accumulation of AIs, reaching concentrations high enough to enable their detection by receptors, which can be intracellular or membrane bound. The binding of AIs to their respective receptor triggers the transcription of quorum-specific genes, as well as genes involved in the synthesis of AIs. 35 Gram-negative and Gram-positive bacteria utilize a range of different QS systems, two common examples of which are shown in Figure  3 . Gram-negative bacteria commonly use acyl-homoserine lactones (AHLs) or other molecules derived from S-adenosylmethionine as AIs. In terms of structure, AHLs consist of an N-acetylated homoserinelactone ring and a carbon acyl chain that can vary in length and contain various modifications. AHLs are synthesized by AHL synthase enzymes, the most common being LuxI-type synthases, which have been found to be expressed in hundreds of bacterial species. Once synthesized inside the cell, AHLs diffuse or get transported across the inner and outer membranes to enter other nearby cells where they bind to their receptors, which are cytoplasmic transcription factors. The most common receptors are the LuxR-type receptors; in the absence of an AHL molecule these receptors fail to fold and are rapidly degraded; however, once an AHL molecule binds to the LuxR-type receptor, it becomes stable, dimerizes and binds to DNA to drive the transcription of quorum-specific genes ( Figure 3 ). 37 Gram-positive bacteria generally employ secreted oligopeptides, collectively referred to as autoinducing peptides (AIPs), as signalling molecules for QS. In terms of structure, some AIPs exist as acyclic oligopeptides and some exist as cyclic lactone peptides. Inside cells, an AIP signal precursor locus is translated into a precursor AIP that is processed to form mature AIPs, which are secreted out of the cell into the extracellular environment. Once the cell population density increases beyond a certain point, the AIPs reach a threshold concentration required for detection and bind to a membrane-bound two-component histidine sensor kinase, which activates its kinase activity, resulting in its autophosphorylation. The activated sensor kinase then transfers the phosphate group to an intracellular response regulator, resulting in its phosphorylation. The phosphorylated response regulator is activated and binds to DNA to drive the transcription of quorumspecific genes ( Figure 3) . 36, 38 Although Gram-negative and Grampositive bacteria utilize different AIs, there are some common AIs, such as AI-2, that mediate interspecies QS. 39 
Efflux pumps in bacteria
Efflux pumps are membrane proteins that are involved in the export of noxious substances from within the bacterial cell into the external environment. They are found in all species of bacteria, and efflux pump genes can be found in bacterial chromosomes or mobile genetic elements, such as plasmids. 40 Efflux pumps can extrude a wide array of substrates, including antibiotics, detergents, dyes, toxins and waste metabolites. 41 They can be specific for a single substrate or can export a wide range of structurally diverse substrates. Efflux pumps that can export several substrates, including multiple different classes of antibiotics, may be associated with MDR. 42 There are five superfamilies of efflux pumps (Figure 4 44 major facilitator superfamily (MFS), 45 ATP-binding cassette (ABC), 46 and resistance-nodulationdivision (RND). 47 To date, RND efflux pumps have only been found in Gram-negative bacteria and are organized as tripartite systems consisting of a cytoplasmic membrane pump, a periplasmic adaptor protein and an outer membrane protein channel. 42 All the efflux pump superfamilies utilize energy from the proton/sodium motive force, except for the ABC superfamily, which are primary transporters that utilize energy from ATP hydrolysis to mediate the efflux of substances from within the cell. 48 Efflux pumps are a key component of drug efflux, which is one of the main mechanisms of antibiotic resistance in bacteria. 7 In Grampositive bacteria, the MFS superfamily of efflux pumps is the most widely studied and includes clinically relevant examples, such as NorA of Staphylococcus aureus, which exports fluoroquinolones and quaternary ammonium compounds. 49 The most clinically significant efflux pumps in Gram-negative bacteria belong to the RND superfamily, which includes AcrAB-TolC of Escherichia coli and Salmonella enterica, and MexAB-OprM of P. aeruginosa and AdeABC of Acinetobacter baumannii. All species of bacteria can express efflux pumps from more than one superfamily and/or more than one type of efflux pump from the same superfamily. 42 In addition, efflux pumps also exhibit different substrate profiles, which vary within and between the superfamilies. 49, 50 Although efflux pumps are widely implicated in antibiotic resistance, there is growing evidence from numerous studies to suggest that they may play a role in a range of bacterial behaviour, including biofilm formation, 51 QS, 52 pathogenicity and virulence. 42 This review will present the current evidence to highlight the role of bacterial efflux pumps in biofilm formation, particularly in several (b) In Gram-positive bacteria, QS is mediated by AIPs, which are translated from an AIP signal precursor locus to produce an AIP precursor, which is then processed to form mature AIPs. They are secreted out of the cell and detected by a sensor kinase that phosphorylates a response regulator, which drives the transcription of quorum-specific genes. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
Review important pathogenic species, such as E. coli, P. aeruginosa, A. baumannii and several other species.
Role of efflux pumps in biofilm formation
Several studies suggest that efflux pumps might play at least four different roles in biofilm formation ( Figure 5 ): efflux of EPSs and/or QS and quorum quenching (QQ) molecules to facilitate biofilm matrix formation and regulate QS, respectively; indirect regulation of genes involved in biofilm formation; efflux of harmful molecules, such as antibiotics and metabolic intermediates; and influencing aggregation through promoting or preventing adhesion to surfaces and other cells. In the following section, the studies that have investigated the role of efflux pumps in biofilm formation by several important pathogenic species, including E. coli and P. aeruginosa, will be discussed and evaluated.
Role of efflux pumps in E. coli biofilm formation E. coli is a Gram-negative bacterium that primarily inhabits the gastrointestinal tract of vertebrates. The majority of E. coli strains are non-pathogenic and are a part of the normal gut flora, where they benefit their hosts by preventing colonization by pathogenic bacteria through the production of bacteriocins and several other mechanisms. 53 However, some strains, such as uropathogenic E. coli (UPEC), neonatal meningitis E. coli (NMEC) and enteroaggregative E. coli (EAEC), can cause urinary tract infection (UTI), neonatal meningitis and infantile diarrhoea, respectively. 54 Importantly, E. coli biofilms exhibit higher resistance to clinically efficacious antibiotics than planktonic cells and display increased expression of several efflux pumps. 55 The first type of studies to report a link between efflux pumps and biofilms examined the expression of efflux genes within biofilms compared with planktonic growth. Studies that have investigated the global gene expression in E. coli biofilms using DNA microarrays found that the expression of several genes encoding putative efflux and transport proteins were upregulated. The transport genes mdtF and lsrA, which belong to RND and ABC superfamilies, respectively, were reported to be expressed at significantly higher levels during biofilm growth compared with exponential-and stationary-phase growth. 56 A study reported that E. coli cells grown under anaerobic conditions displayed a 20-fold greater expression of the MdtEF efflux pump compared with control, and a mutant strain lacking the mdtEF gene had significantly lower survival rates under anaerobic respiration of nitrate. In addition, the mutant strain lacking mdtEF was significantly more susceptible to nitrosyl indole derivatives, suggesting that MdtEF may be involved in their efflux. 57 Anaerobic conditions are common in the core of biofilms as the cells in the outer regions of the biofilm actively respire most of the available oxygen, 58 which may cause facultative anaerobes such as E. coli to switch to anaerobic respiration; hence up-regulation of the MdtEF pump may protect cells from damage due to nitrosyl indole derivatives by facilitating their efflux. The lsrA gene encodes a component of the LsrABCD complex, which mediates the transport of AI-2, a signalling molecule that facilitates QS in E. coli. 59 The up-regulation of lsrA suggests that efflux pumps may play a role in the transport of AIs in E. coli biofilms, which may facilitate QS within the biofilm, thereby promoting biofilm maturation. Another study reported that the expression of yihN, an MFS-encoded efflux gene, was 2-fold greater in E. coli K-12 biofilms compared with planktonic exponential cultures. However, the biofilm phenotype of a yihN mutant was not determined, 60 and thus it is unknown whether yihN expression is required for biofilm formation. In another study, the mdtQ gene was reported to be expressed at levels 14-fold greater in E. coli biofilms grown on mild steel plates compared with suspension cells. 61 Reported possible substrates of this efflux protein include acriflavine, puromycin and tetraphenylarsonium chloride, 62 but it is possible that there may be other substrates of Some studies have focused specifically on the expression of efflux pumps in E. coli biofilms. Kvist et al. 63 reported that there was up-regulation of 20 efflux pump and transport genes within biofilms formed by two different UPEC strains compared with E. coli F-18 strain. Of these, the expression of genes in the aaeXAB operon, as well as mdtL, mdtG, setB and yqgA genes, was found to be increased most during biofilm growth. Previously, the expression of the RND pump AaeAB was shown to be up-regulated when E. coli cells were treated with p-hydroxybenzoic acid (pHBA), which is an intermediate of ubiquinone biosynthesis and is normally present at low levels. Furthermore, the AaeAB pump was reported to exhibit a very narrow substrate specificity, which was limited to several aromatic hydroxylated carboxylic acids, including pHBA. Hence, it was proposed that the AaeAB pump may function as a 'metabolic relief valve' to regulate the levels of intracellular metabolites by driving the efflux of excess metabolites, such as pHBA. 64 It is possible that the up-regulation of the AaeAB pump during biofilm formation may function to prevent the toxic accumulation of metabolites within cells. The MFS pump SetB has been previously demonstrated to be involved in the efflux of glucose, 65 which is a major component of the extracellular biofilm matrix. 66 Hence, the up-regulation of setB expression during biofilm growth may serve to export sugars to promote the synthesis of the biofilm matrix, but may also act to export non-metabolizable sugars that could be toxic to biofilm cells. May et al. 67 determined that the overexpression of the MFS efflux pump TetA(C) contributes to the osmotic stress response and is involved in the induction of colanic acid production, a capsular polysaccharide component of the matrix that promotes E. coli biofilm maturation. Furthermore, the efflux genes araJ, ddpD, emrK, gltK, ycbO and yhdX were reported to be upregulated .2-fold during biofilm growth compared with planktonic cells. These genes encode efflux pumps that have been predicted to facilitate the transport of several different substrates that may promote biofilm formation. The ABC transporter protein YhdX is thought to be part of the YhdWXYZ system and is predicted to play a role in the transport of L-amino acids across the membrane. 68 L-Amino acids are important components of the biofilm matrix where they contribute to biofilm stability by forming electrostatic interactions, hydrogen bonds, hydrophobic interactions and van der Waals interactions with other molecules and one another. 13 The MFS efflux pump AraJ may play a role in the transport or processing of arabinose polymers, but its definitive function remains unknown and requires further investigation. 69 Arabinose is a monosaccharide that is a part of the biofilm matrix and plays a role in cell aggregation. 70 If AraJ does indeed facilitate the transport of arabinose, the up-regulation of araJ expression may benefit cells by allowing accelerated efflux of arabinose to promote cell aggregation and biofilm matrix formation.
The role of efflux pumps in E. coli biofilm formation has been reported in several gene inactivation studies. Junker et al. 71 exposed WT E. coli cells to Tn5 transposon mutagenesis and grew the cells under biofilm and planktonic conditions. Using gene arrays, it was reported that the three efflux genes emrY, fsr and ydeA were important for biofilm growth. The emrY and fsr genes Review both encode MFS-type putative drug resistance efflux pumps. 72, 73 Prominently, the MFS efflux pump SotB encoded by the ydeA gene has been shown to be involved in the efflux of sugars, such as arabinose, 74 and may also be involved in the efflux of toxic sugars and sugar metabolites. As mentioned before, arabinose is a component of the biofilm matrix and promotes aggregation; 70 therefore the expression of efflux pumps that transport arabinose or other sugars is probably critical for biofilm formation. Matsumura et al. 75 employed 22 mutant strains of E. coli K-12 that were lacking various efflux pump genes and found that all the strains displayed decreased biofilm formation. Furthermore, mutants missing the acrD, acrE, mdtE (RND superfamily), emrD, emrK (MFS superfamily) and emrE (SMR superfamily) efflux genes exhibited extremely low biofilm formation compared with WT strain. The EmrD efflux pump has been reported to be involved in the efflux of arabinose, 74 which as previously mentioned promotes cell aggregation and biofilm matrix formation. 70 The EmrE efflux protein has been previously reported to drive the efflux of cationic osmoprotectants, such as betaine and choline. 76 Osmoprotectants are critical for bacterial cells to maintain osmotic homeostasis. 77 Thus, the mutant strain lacking the emrE gene may not be able to form biofilm due to its inability to maintain osmotic homeostasis during the initial stages of biofilm formation. Another study reported that the AcrB and MdtABC pumps of the RND superfamily contribute to the maintenance of biofilm. 78 A mutant strain that was missing both acrB and mdtABC genes displayed normal biofilm formation at 4 h, which then diminished over time and was reduced significantly at 24 h. This study suggested that AcrB and MdtABC are not involved in the efflux of substrates required for biofilm formation as the mutants were still able to form a biofilm, but rather they export substrates that are essential to maintain a biofilm. Recently, a study by Bay et al. 79 found that E. coli mutant strains lacking the efflux genes acrB, acrE and tolC displayed significant reductions in biofilm growth and exhibited increased antimicrobial susceptibility compared with WT control. The mutant strain lacking tolC was reported to exhibit the most severe reduction in biofilm cell viability, which is not surprising since TolC performs many different functions within bacteria. Therefore, it is difficult to differentiate the direct and indirect consequences of TolC deletion, as its absence also affects permeability and the presence of other proteins in the outer membrane. 80 Mutant strains lacking the efflux genes acrD, emrA, emrB, emrE, mdtK or mdtJ were reported to display enhanced biofilm growth compared with control. The enhanced biofilm growth displayed by mutant strains lacking acrD and emrE was contrary to the results obtained by Matsumura et al., 75 where these mutants displayed impaired biofilm growth compared with control. Bay et al. 79 noted that the explanation for the different findings between the two studies was likely to be due to the differences in the experimental conditions used in the two studies. Therefore, it is crucial to consider the surface on which biofilms are grown on and the growth conditions used when interpreting results from studies, because, as demonstrated by Bay et al., 79 these factors do influence the results obtained in studies. As listed in Table 2 , there is a diverse range of efflux pumps from different families with very different substrates that have been reported to play a role in biofilm formation by E. coli. In particular, reported results from studies so far indicate that MFS-and RND-type efflux pumps seem to play a bigger role in biofilm formation than other families.
Role of efflux pumps in P. aeruginosa biofilm formation P. aeruginosa is a Gram-negative bacterium that naturally inhabits the soil and bodies of water. In addition, it can colonize and survive in a wide range of natural and artificial environments due to its adaptability and intrinsic resistance. 82 Clinically, it is an important opportunistic pathogen that is one of the main causes of both nosocomial infections in patients with compromised host defence and chronic infections in cystic fibrosis patients. 83 Furthermore, the intrinsic antibiotic resistance exhibited by P. aeruginosa is more prominent in biofilms, which limits the therapeutic options available for the treatment of P. aeruginosa biofilm infections. The WHO has designated carbapenem-resistant P. aeruginosa as the second most important MDR pathogen in terms of the threat it poses to human health, and has declared that novel antibiotics for this pathogen are urgently required. 6 The role of efflux pumps in P. aeruginosa biofilm formation has been suggested in numerous studies. As noted above, QS is necessary for the development of P. aeruginosa biofilms, 84, 85 and so efflux pumps may play a role in the transport of important components required for biofilm formation, such as AHLs. One of the earliest studies demonstrated that WT P. aeruginosa cells treated with azide, a cytoplasmic membrane proton gradient inhibitor, exhibited strong intracellular accumulation of N-3-oxododecanoyl-L-homoserine lactone (3OC12-HSL), an important AHL that facilitates QS in P. aeruginosa, suggesting the involvement of active efflux. 83 Furthermore, P. aeruginosa mutants lacking the mexABoprM-encoded efflux pump also showed strong intracellular accumulation of 3OC12-HSL and reduced biofilm formation. This study suggested that 3OC12-HSL is a natural substrate of MexAB-OprM and is involved in its efflux. A few years later, the macrolide azithromycin was shown to reduce biofilm formation by interfering with the production of 3O12-HSL and N-butyryl-L-homoserine lactone (C4-HSL), suggesting that both 3OC12-HSL and C4-HSL play a significant role in biofilm formation. 86 This was confirmed by the addition of both molecules in the presence of azithromycin, which resulted in a significant recovery of biofilm formation. Hence, it is evident that the MexAB-OprM pump plays an important role in P. aeruginosa QS by driving the efflux of AHLs, such as 3OC12-HSL, which are required for biofilm formation. Efflux pumps have been suggested to play a role in the transport of AHLs in other species too; Burkholderia cenocepacia mutants lacking two different RND-encoding genes, BCAL1675 and BCAL2821, have been shown to exhibit significantly less accumulation of AHL in growth media compared with WT strain, 87 and Burkholderia pseudomallei mutants lacking the RND efflux gene bpeAB have been reported to exhibit significant intracellular accumulation of AHLs upon exogenous administration. 88 Some studies have investigated the effects of the overexpression of efflux pumps on P. aeruginosa biofilm formation. Sánchez 89 reported that P. aeruginosa nalB and nfxB mutants, which overexpress MexAB-OprM and MexCD-OprJ efflux systems, respectively, did not display any defects in biofilm formation and, in fact, the nalB mutant strains were reported to exhibit significantly denser biofilm formation compared with WT. As mentioned before, the MexAB-OprM pump plays a role in the efflux of 3OC12-HSL, and thus the overexpression of the MexAB-OprM pump in nalB mutants may enable enhanced efflux of AHLs to mediate rapid biofilm Review JAC formation, which could explain the denser biofilms formed by nalB mutants. Another study reported that mutants overexpressing the MexEF-OprN pump displayed an impairment in biofilm formation. 85 MexEF-OprN has been shown to drive the efflux of 4-hydroxy-2-heptylquinoline, a precursor of the Pseudomonas quinolone signal (PQS), which is one of the AIs utilized by P. aeruginosa to facilitate QS. 90 It may be that the overexpression of MexEF-OprN reduces the intracellular concentration of QS signals in an individual cell or group of cells to decrease its quorum response, which would result in the impairment of biofilm formation.
Several studies have also reported that the expression of efflux pumps is increased in P. aeruginosa biofilms. Waite et al. 91 compared the transcriptomes of planktonic cultures and developing biofilms. It was reported that expression of the efflux genes PA2114, PA4502, PA4505 and PA4506 was up-regulated .2.5-fold in developing biofilms compared with planktonic growth. The P2114 gene encodes a putative MFS transporter and the PA4502, PA4505 and PA4506 genes each encode components of putative ABC transporters, with unknown substrate specificities; 92 therefore the role of these pumps in biofilm formation remains unknown. Gillis et al. 86 reported that the MexCD-OprJ efflux system was upregulated in P. aeruginosa biofilms and that mexAB-oprM and mexCD-oprJ efflux systems were essential for biofilm formation in the presence of azithromycin. On the other hand, another study reported that overall expression of the efflux genes mexAB-oprM and mexCD-oprJ decreased over time in developing biofilms.
The reason for the conflicting reports could be because biofilm establishment may require different systems compared with biofilm maintenance. In the same study, there was also evidence of spatial variation in the expression of efflux pumps within the biofilm. For instance, mexAB-oprM and mexCD-oprJ expression were found to be greatest at the biofilm substratum, 23 where cells are near both to one another and to the surface to which they are attached, which restricts diffusion. Therefore, it is probable that increased expression of efflux pumps in the substratum may be required for the sufficient efflux of secondary metabolites and waste metabolites produced by intracellular reactions to prevent toxic accumulation inside cells. 51 Previously, the MexCD-OprJ pump has been reported to be up-regulated in P. aeruginosa cells when exposed to waste water, 93 which suggests a protective role for MexCD-OprJ against waste compounds. As mentioned previously, anaerobic conditions are often found in the core of biofilms, 58 and therefore the up-regulation of mexAB-oprM and mexCD-oprJ may act to protect biofilm cells in the substratum by exporting the waste metabolites produced during anaerobic respiration.
A transcriptomic analysis of P. aeruginosa biofilm development reported that the expression of the efflux genes mexG and mexH was up-regulated .3-fold in biofilms compared with planktonic cells. Furthermore, the efflux genes mexF and mexX were reported to be up-regulated during biofilm formation over time from 24 to 96 h compared with the expression levels at 16 h. 
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Zhang and Mah 95 described a novel ABC efflux pump, encoded by PA1874-1877 genes, which was found to be expressed at higher levels in biofilms compared with planktonic growth. In addition, this pump was shown to confer resistance to aminoglycosides and ciprofloxacin in biofilm cells, but not in planktonic cells. Therefore, this efflux pump may play a role in biofilm-specific resistance.
Recently, a study reported that the MexGHI-OpmD efflux system of P. aeruginosa was involved in the transport of the endogenous and reactive antibiotic 5-methylphenazine-1-carboxylate (5-Me-PCA). Furthermore, it was shown that 5-Me-PCA was required for the morphogenesis of WT colony biofilms. It was proposed that 5-Me-PCA might be employed by cells in hypoxic areas of biofilms for redox balancing, which may contribute to the survival of cells. 96 Previously, MexGHI-OpmD was also shown to facilitate QS in P. aeruginosa. Aendekerk et al. 97 reported that mutant P. aeruginosa strains lacking mexI and opmD genes were unable to synthesize 3-oxo-C12-HSL and PQS. Furthermore, both mutant strains displayed impaired growth and were avirulent in rat and plant infection models. Whether, MexGHI-OpmD drives the efflux of these AIs remains to be investigated, but these studies suggest that this pump plays an essential role in facilitating P. aeruginosa QS and virulence, and therefore may also play a role in biofilm formation.
As listed in Table 3 , RND-type efflux pumps seem to play a significant role in biofilm formation by P. aeruginosa, highlighting their importance. There may also be efflux pumps from other superfamilies that play a role in biofilm formation that have yet to be investigated, such as MATE-, SMR-and MFS-type pumps.
Role of efflux pumps in biofilm formation by other bacterial species
Although research into the role of efflux pumps in biofilm formation has been conducted largely in E. coli and P. aeruginosa, several other bacterial species have also been studied and found to demonstrate links between efflux pumps and biofilm formation. These species include A. baumannii, Proteus mirabilis, S. enterica serovars, Listeria monocytogenes and S. aureus.
A. baumannii
A. baumannii is a Gram-negative bacterium that is an important opportunistic pathogen commonly encountered in clinical settings, where it causes a range of diseases, such as bacteraemia, pneumonia, meningitis and urinary tract infections. According to a recent report by the WHO, carbapenem-resistant A. baumannii is the MDR pathogen that poses the greatest threat to human health and for which novel antibiotics are urgently required. 6 Clinical isolates of A. baumannii have been observed to readily form biofilms, and biofilm formation is thought to be responsible for the chronic infections caused by A. baumannii. When treated with subinhibitory concentrations of antibiotics, biofilm formation by A. baumannii is even more widespread and this causes difficulty in the treatment of A. baumannii infections due to increased tolerance of clinical antibiotics. 98 The role of efflux pumps in A. baumannii biofilm formation has been suggested in whole transcriptome analysis of biofilm and planktonic cells. Rumbo-Feal et al. 99 reported that the expression of the RND efflux genes A1S_0009, A1S_0116 and A1S_0538, and the MFS efflux gene A1S_1316 was up-regulated in biofilm compared with stationary-and exponential-phase cells. Out of the four up-regulated efflux genes, A1S_0116 was reported to be upregulated by the greatest amount, whilst A1S_0009 was upregulated by the least. Furthermore, the efflux genes A1S_1117, A1S_1751 and adeT were reported to be only expressed in biofilm cells and not in planktonic cells. A1S_1117 encodes a predicted sugar transporter protein belonging to the MFS, A1S_1751 encodes an AdeA membrane fusion protein, and adeT encodes an RNDtype efflux pump involved in aminoglycoside resistance. How these efflux pumps contribute to biofilm formation remains to be investigated, but it seems possible that the MFS sugar transporter encoded by the A1S_1117 gene may facilitate the efflux of sugars, which make up the biofilm matrix. 13 A few studies have investigated the role of RND efflux pumps in A. baumannii biofilm formation. He et al. 100 reported that biofilm formation by clinical isolates of A. baumannii was associated with an overexpression of the AdeFGH efflux pump. Furthermore, the greatest induction of biofilm was observed with the consistent upregulation of abaI and abeG genes, which encode an AHL synthase required for biofilm development and a component of the AdeFGH efflux pump, respectively. The authors suggested that the overexpression of the AdeFGH efflux pump presumably accelerates the efflux of AHLs during biofilm formation, although the role of AdeFGH in the efflux of substrates required for biofilm formation has not yet been investigated. Another study reported that mutants overexpressing the AdeABC, AdeFGH and AdeIJK efflux pumps displayed significant reduction in biofilm formation compared with WT strain. Furthermore, the deletion of the efflux genes adeG and adeJ was reported to restore the biofilm, although the mutant strain lacking adeB still exhibited significant defects in Table 3 . Efflux genes that have been reported to play a role in biofilm formation by P. aeruginosa, along with the type of efflux pump they encode, their likely substrates and the effect of gene knockout on biofilm formation 101 This suggests that biofilm formation in A. baumannii requires a certain expression profile of efflux pumps to initiate and maintain biofilm formation, and that some efflux pumps are more critical than others in this respect. In mutants overexpressing the adeABC and adeIJK efflux genes, there was an associated underexpression of several genes encoding proteins CsuA/B, CsuC and FimA. These proteins belong to pilus systems that play a key role in the initial stages of biofilm formation, where they promote initial adhesion, surface colonization and formation of microcolonies. 101 This may explain why the mutant strains overexpressing the AdeABC and AdeIJK pumps exhibited reduced biofilm formation; the down-regulation of genes involved in pilus systems would impair the initial stages of biofilm formation. Therefore, the AdeABC and AdeIJK efflux systems may indirectly regulate expression of pilus genes by exporting molecules that activate regulator genes. Richmond et al. 102 investigated the ability of different strains of A. baumannii adeB knockout mutants to form biofilms on abiotic and biotic surfaces. The adeB knockout A. baumannii AYE mutant strain exhibited a significant reduction in biofilm formation on both plastic and mucosal tissue compared with WT. The adeAB knockout A. baumannii S1 mutant strain exhibited significant reduction in biofilm formation on mucosal tissue but not plastic. On the other hand, the deletion of adeB in A. baumannii ATCC 17978 strain was reported to result in a significant increase in biofilm formation compared with WT. These studies highlight that different A. baumannii strains have different responses to adeB deletion and that the role of the AdeB efflux pump in biofilm formation may differ between strains, possibly related to endogenous levels of adeABC expression.
A recent study reported that the A1S_0114 gene within the QS-regulated operon A1S_0112-A1S_0119 of A. baumannii ATCC 17978 strain was involved in adhesion, biofilm formation and virulence. 103 A mutant strain lacking the A1S_0114 gene was unable to form mature biofilms and displayed significant reduction in adhesion and virulence in three different experimental animal models. A1S_0114 was reported to be involved in the synthesis of a lipopeptide-like compound named acinetin 505 (Ac-505), which was proposed to play a role in A. baumannii adhesion, biofilm formation and virulence. Significantly, another gene called A1S_0116 in the same operon was found to encode an RND efflux pump, which may facilitate the efflux of Ac-505 during biofilm formation. It may be worth investigating whether the deletion of A1S_0116 inhibits biofilm formation and maturation, and whether the Ac-505 molecule is necessary for biofilm formation.
P. mirabilis
P. mirabilis is a species of highly motile Gram-negative bacteria and a member of the Enterobacteriaceae, related to E. coli, that commonly causes catheter-associated urinary tract infections in clinical settings. As a pathogen, it exhibits potent urease expression, which results in ammonia production that increases the local urinary pH within catheters. The alkaline conditions lead to the precipitation of calcium and magnesium phosphates that form crystals in the developing biofilm, ultimately resulting in the formation of crystalline biofilms that block the urinary catheter. This crystalline deposition and encrustation causes urinary retention within catheters, leading to urinary tract infections. 104 The role of efflux pumps in biofilm formation by P. mirabilis has been investigated using random transposon mutagenesis. Holling et al. 105 reported that disruption of the bcr efflux gene led to reduced crystalline biofilm formation, resulting in less catheter blocking. Furthermore, the bcr mutant was also deficient in both swarming and swimming motility. In P. mirabilis, the MFS efflux pump bicyclomycin resistance protein has not been studied extensively, therefore its substrates remain unknown. Recently, Nzakizwanayo et al. 106 demonstrated that fluoxetine and thioridazine inhibited efflux in P. mirabilis, which was predicted through molecular modelling to be partly due to the inhibition of the Bcr/ CflA efflux system. Furthermore, both drugs were found to significantly reduce the rate of crystalline biofilm formation in catheters and increase the time taken for catheter blockage. This suggests that it is possible to experimentally induce the same effects on biofilm growth and catheter blockage by using inhibitors predicted to block these efflux pumps. In E. coli, which is related to P. mirabilis, this efflux pump is involved in sulphonamide and bicyclomycin resistance. 107 In addition, it has also been reported to be involved in the export of short peptides, such as dipeptides. 108 As mentioned previously, the biofilm matrix consists of EPSs, including peptides, 13 and therefore this efflux pump may function to efflux peptides that comprise the biofilm matrix or, in the absence of clear definitions of QS in Proteus, perhaps short, peptide-derived QS molecules.
S. enterica serovars
S. enterica serovars are Gram-negative bacteria that cause several different diseases in humans, including enteric fever, gastroenteritis and bacteraemia. 109 They have been reported to form biofilms on abiotic surfaces, such as plastic, rubber and stainless steel, and on biotic surfaces, such as plants, animal epithelial cells and gallstones. S. enterica serovar biofilms are recalcitrant to antimicrobial treatment and can persist on a diverse range of surfaces in both host and non-host environments, 110 causing recurrent infections and making treatment problematic.
Evidence for the role of efflux pumps in biofilm formation by S. enterica serovars emerged from a study by Baugh et al., 111 who investigated 10 efflux deletion mutants of S. enterica serovar Typhimurium and their ability to form biofilms. The deletion of the efflux genes acrB, acrD, acrEF, emrAB, macAB, mdfA, mdsABC, mdtABC, mdtK and tolC resulted in decreased biofilm formation compared with WT strain. The RND pump AcrD has also been suggested to be involved in several processes important to Salmonella biology. Buckner et al. 112 reported that inactivation of the acrD gene led to transcriptomic changes relating to environmental sensing, metabolism, pathogenicity and stress response pathways. It may be that AcrD functions to transport molecules that regulate the genes involved in these processes, including biofilm formation. The ABC efflux pump MacAB-TolC has been proposed to be involved in the efflux of protoporphyrin, the intermediate haem precursor, in E. coli and S. enterica serovar Typhimurium. 113 This is suggestive of a functional role for the MacAB-TolC efflux pump in biofilm formation, where it may regulate natural haem homeostasis within biofilm cells through the efflux of excess haem intermediates. The RND efflux pump MdsABC has a broad substrate range, including acriflavine, benzalkonium chloride, detergents, dyes, gold and novobiocin. 114, 115 In addition, it has also Review been reported to play a role in pathogenicity and resistance to extracellular oxidative stress-inducing agents, such as diamide, hydrogen peroxide and Paraquat. 116 Due to its broad substrate range, MdsABC may function to protect cells from a range of chemical insults during biofilm formation. The MATE superfamily efflux pump MdtK can efflux acriflavine, doxorubicin and norfloxacin, 115 but interestingly it has also been reported to efflux dipeptides, such as alanylglycine in E. coli.
108 Dipeptide-like compounds in the natural environment have been shown to function as antimicrobial agents, and certain cyclic dipeptides, such as cycloalanylvaline, have been reported to function as QS molecules in P. aeruginosa and several other Gram-negative species. 117 Furthermore, MdtK in E. coli has .90% sequence similarity with MdtK in S. enterica serovar Typhimurium, highlighting that MdtK is highly conserved amongst members of the Enterobacteriaceae family. 108 Therefore, MdtK may function to efflux dipeptides or dipeptide-like compounds in S. enterica biofilm cells to prevent accumulation of antimicrobial dipeptides and possibly facilitate QS through the efflux of cyclic dipeptides. Baugh et al.
111 also investigated the expression levels of the csgB and csgD genes, which encode components of curli, a protein filament present on cell surfaces and an important component of the Salmonella biofilm matrix. All the efflux mutants expressed significantly lower levels of csgB and csgD when compared with WT strains. It may be that these efflux pumps are involved in the export of molecules that regulate activators of the genes encoding curli; however, this remains to be investigated.
As listed in Table 4 , a range of efflux pumps from different superfamilies play a role in biofilm formation by S. enterica serovars, although RND-type pumps seem to play a predominant role. Interestingly, unlike in E. coli and P. aeruginosa, no efflux pump in S. enterica serovars has been implicated in the efflux of QS molecules.
L. monocytogenes
L. monocytogenes is a Gram-positive pathogen that is the causative agent of listeriosis, which is acquired by consuming contaminated food products. 119 It is commonly found on food surfaces and in facilities involved in food processing, where it persists for long periods of time. It is thought that the persistence of L. monocytogenes is due to its ability to form biofilms, which confers resistance to antibiotics, biocides and detergents. 120 Two studies by Zhu et al. 121, 122 reported a relationship between efflux pumps and biofilm formation by L. monocytogenes. Zhu et al. 121 identified a novel ABC transporter called Lm.G 1771 and noted that when one of the components of the transporter was inactivated by a mutation, the resulting strain exhibited a significant increase in biofilm formation compared with WT strain. Lm.G 1771 was reported not to exhibit sequence similarity to any of the existing transporters of signalling molecules, and was therefore proposed to be a novel transporter that may drive the transport of a novel bacterial signalling molecule. A further study by Zhu et al. 122 investigated the phenotypic, proteomic and genomic characterization of Lm.G 1771 by using an Lm.G 1771 genedeletion mutant. DNA microarrays and two-dimensional gel electrophoresis revealed that several cell surface proteins, cell surface anchor proteins and transcriptional regulators of biofilm formation were expressed differentially in Lm.G 1771 gene deletion mutants compared with WT. This study suggests that some efflux pumps may hinder biofilm formation by altering the expression of genes involved in biofilm formation. The substrates of Lm.G 1771 and the effects of its overexpression on L. monocytogenes biofilm formation remain unknown.
S. aureus
S. aureus is a Gram-positive bacterium that is a major cause of both nosocomial and community-acquired infections. Most notably, MRSA strains, which are resistant to nearly all the clinically efficacious b-lactam antibiotics, are an important cause of nosocomial infections worldwide. S. aureus can form biofilms, which increases tolerance to different classes of antibiotics, increasing persistence and rendering treatment problematic. 123 Several studies have investigated the role of efflux pumps in S. aureus biofilms by analysing the expression levels of efflux pumps in S. aureus biofilms. An early study investigated the global gene expression in biofilms of clinical isolates of S. aureus. It was reported that the expression of several efflux and transporter genes was altered during biofilm growth compared with Table 4 . Efflux genes that have been reported to play a role in biofilm formation by S. enterica serovars, along with the type of efflux pump they encode, their likely substrates and the effect of gene knockout on biofilm formation Review JAC stationary-and exponential-phase cells. Two uncharacterized efflux pump genes, SA2261 and SA2131, were reported to be down-regulated during biofilm growth. 124 Since not much is known about these two genes and their products, it is difficult to infer how they contribute to biofilm formation. A comparative transcriptome analysis of S. aureus cells under planktonic and biofilm conditions revealed that the expression of several transport genes was higher in biofilm than in planktonic growth. The expression of genes within biofilm was analysed over time, starting at 6 h and ending at 48 h of biofilm growth. Genes expressed at 6 and 8 h were more likely to be involved in biofilm formation than the genes expressed much later at 48 h. Of the genes expressed highly in biofilm at 8 h, the SA0589, SA2142 and proP genes were reported to be expressed at least 5-fold more in biofilm than in planktonic growth. 125 The SA0589 and SA2142 genes, respectively, encode proteins that are putative ABC and MFS MDR proteins with unknown substrate profiles, 126 and thus it is difficult to infer how these proteins play a role in biofilm formation. As previously suggested, the proP gene encodes a putative proline/betaine transporter that belongs to the MFS family, which may be involved in the transport of osmolytes, such as proline and glycine betaine. 126 A gene called SE0225, which encodes the glycine/betaine transporter OpuCD, was also observed to be up-regulated by at least 3-fold in Staphylococcus epidermis biofilms compared with planktonic growth. 127 Osmolytes are critical for bacterial cells to survive during osmotic stress, 77 and thus the up-regulation of osmolyte transporters may be essential to protect cells from osmotic stress by facilitating the transport of osmolytes across the membrane during the initial stages of biofilm formation. It has been reported that the relative expression levels of the efflux pump genes mdeA, norB and norC were up-regulated in S. aureus during biofilm growth. 128 These three genes encode MFS efflux pumps; NorB and NorC efflux pumps can export cetrimide, ethidium bromide, quinolones and tetraphenylphosphonium, 129 whilst the MdeA efflux pump can export a range of quaternary ammonium compounds and antibiotics. 130 It has been reported that norB expression is upregulated in S. aureus in response to acid shock and reduced aeration, suggesting that NorB may be involved in the response to hypoxic conditions and low pH within biofilms. 131 These conditions are often encountered within the core of biofilms and S. aureus switches to anaerobic respiration to generate ATP. Previously, Zhu et al. 132 demonstrated that fermentation of glucose by S. aureus during biofilm growth resulted in an accumulation of organic acids, such as acetic acid, formic acid and lactic acid, which in turn decreased the pH. Organic acids inhibit the growth of S. aureus and can trigger stress response pathways; 133 thus NorB may function to ensure that biofilm cells are protected from the toxic effects of organic acids produced during anaerobic respiration. It would be interesting to investigate the spatial expression of norB within S. aureus biofilms.
Tu Quoc et al. 134 created an insertional mutant library in a highly biofilm-forming clinical isolate of S. aureus and characterized and isolated several genes that when disrupted caused defective biofilm formation. One of the genes characterized was called bfd2, which encodes a hypothetical protein showing characteristics of the MFS, although its substrate specificity is currently unknown. Studies have also shown that MgrA, a pleiotropic regulator in S. aureus, acts as a negative regulator of the efflux pumps NorB and NorC 135 and represses biofilm formation, 136 suggesting a link between efflux pump activity and biofilm formation in S. aureus. As listed in Table 5 , only MFS-type efflux pumps have been reported to play a role in biofilm formation by S. aureus. Furthermore, the biofilm phenotype of the majority of efflux genes in S. aureus has yet to be determined.
Effects of efflux pump inhibitors (EPIs) on biofilm formation
As discussed previously, efflux pumps play various roles in biofilm formation; hence inhibiting their function could also inhibit biofilm formation. Compounds that inhibit the function of efflux pumps are known as EPIs. Several studies have demonstrated that some EPIs significantly reduce biofilm formation in certain bacterial species ( Figure 6 ). One of the earliest studies reported that the proton motive force (PMF) inhibitor CCCP significantly reduced biofilm formation by epidemiological isolates of P. aeruginosa. 137 Later, Kvist et al. 63 reported that addition of the EPIs 1-(1-napthylmethyl) piperazine (NMP), PABN and thioridazine significantly decreased biofilm formation by WT E. coli strain F18, uropathogenic E. coli strain 83972 and WT K. pneumoniae strain i222-86, in almost all cases. Treatment with 50 mg/L thioridazine or PABN was reported to reduce biofilm formation by up to 80% compared with controls without any EPIs. However, treatment with 100 mg/L NMP alone did not display any significant anti-biofilm activity compared with control. Furthermore, the combination of EPIs demonstrated synergistic action against biofilm formation when compared with controls. For instance, the combination of thioridazine and PABN decreased biofilm formation by E. coli and K. pneumoniae strains by .95% compared with control. Interestingly, NMP only exhibited anti-biofilm activity when used in tandem with another EPI, such as thioridazine. The effects of EPIs on biofilm formation were also tested on species that do not belong to the family Enterobacteriaceae. Thioridazine or PABN at 20 mg/L was effective in significantly reducing biofilm formation in well-characterized biofilm-forming strains of Pseudomonas putida and S. aureus. As with E. coli and K. pneumoniae, NMP did not exhibit any significant antibiofilm activity against P. putida and S. aureus, although only 20 mg/L NMP was tested, which is lower than the concentration tested against E. coli and K. pneumoniae strains. Synergistic action of EPIs was not observed in P. putida, probably due to the differences in the expression profile of efflux pumps compared with members of the Enterobacteriaceae. Synergistic action of EPIs was not observed in S. aureus either, most likely due to the fact that RNDtype efflux pumps are not found in Gram-positive bacteria. Liu et al. 138 reported that PABN when combined with several iron chelators, such as acetohydroxamic acid, EDTA and 2,2-dipyridyl, exhibited synergistic anti-biofilm activity against P. aeruginosa compared with PABN treatment alone. The combination of PABN and EDTA was reported to be the most promising, causing a 2.5-fold decrease in biofilm biomass compared with control. Iron functions as an important signal for P. aeruginosa biofilm formation, and thus iron chelators prevent biofilm formation by reducing the concentration of iron available to cells. 139 Fiamegos et al.
140
identified and characterized a compound called 4 0 ,5 0 -O-dicaffeoylquinic acid from the plant Artemisia absinthium, which was shown to display anti-biofilm activity in S. aureus and Enterococcus faecalis.
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Furthermore, the compound was also reported to be an effective EPI of MFS efflux pumps, which play a critical role in the MDR of Gram-positive bacteria. A different study conducted on clinical isolates of K. pneumoniae reported that the EPI reserpine was effective in inhibiting biofilm formation at a concentration of 26 lM. Several other compounds were also shown to inhibit biofilm formation; however, it is unknown whether they exhibit EPI activity. 141 Baugh et al. 142 reported that the EPIs CCCP, chlorpromazine and PABN could reduce biofilm formation by E. coli, S. aureus and S. enterica serovar Typhimurium under static and flow conditions. In the study, 2 mg/L CCCP was shown to be sufficient to decrease S. aureus biofilm formation by 5-fold and 16 mg/L PABN was enough to prevent biofilm formation by E. coli. P. aeruginosa required very high concentrations of the EPIs to prevent biofilm formation. Nonetheless, all three compounds tested were below the MIC of each EPI. Thus, they were acting as anti-biofilm agents to reduce biofilm formation rather as antibacterial agents.
CCCP is a broad-spectrum efflux inhibitor that inhibits all efflux pumps that rely on the PMF to function. 143 Furthermore, CCCP has membrane-permeabilizing effects, which have been reported to affect other important processes within bacterial cells, including cell division 144 and metabolism. 145 This may explain why CCCP is more effective in reducing biofilm formation than other EPIs, as it presumably works in several different ways to disrupt biofilm formation. However, this also means that it is difficult to conclude whether the anti-biofilm activity of CCCP is directly due to its ability to inhibit efflux pumps. On the other hand, PABN has been reported in several studies to be a specific competitive inhibitor of RND pumps, acting by recognizing and binding to the same binding site as the substrates of the pumps. 143 However, Lamers et al. 146 also reported that PABN permeabilizes the outer membrane of Gramnegative bacteria, and may also have other cellular effects in bacteria. Similarly, PABN may also affect the permeability of Grampositive bacteria, which may explain why it can also inhibit biofilm Review JAC formation by S. aureus. 142 The mechanism by which phenothiazines inhibit efflux remains to be elucidated, as there seem to be contradictory reports in the literature. Bailey et al. 147 reported that chlorpromazine reduced the levels of acrB in S. enterica serovar Typhimurium, suggesting that chlorpromazine mediated its EPI activity by interfering with the expression of AcrB. Chan et al. 148 reported that several phenothiazines, including chlorpromazine, inhibit efflux by directly interfering with the substrate-pump interaction and to a lesser extent by disrupting the PMF. Dutta et al. 149 reported that Mycobacterium tuberculosis exposure to thioridazine increased the expression levels of the efflux gene emrE. Bonde et al. 150 reported that thioridazine did not affect the expression levels of the efflux genes norA and abcA in MRSA. Therefore, the exact mechanisms by which phenothiazines reduce biofilm formation remain unclear.
As discussed above, some EPIs have been shown to exhibit anti-biofilm activity due to their ability to inhibit efflux. However, there are numerous other EPIs isolated from natural sources 151 and synthetic sources 152 that have yet to be tested for anti-biofilm activity. Indeed, it is evident that EPIs have the potential to be utilized as anti-biofilm agents and used in conjunction with antibiotics to overcome antibiotic resistance. The only EPI to enter a clinical trial was MP-601205, which was tested in cystic fibrosis patients during a Phase 1b trial. However, the trial was eventually discontinued due to toxicity-related issues of the compound. 153 Therefore, none of the EPIs developed so far have been licensed for clinical use. The main reason for this is toxicity, which stems from the fact that most EPIs require high doses to be efficacious, 154 restricting systemic use. However, it may be possible to use EPIs locally rather than systemically. For instance, application of EPIs onto medical devices, such as catheters, could prevent biofilm formation and the emergence of antibiotic-resistant pathogens. A patent has claimed that enveloping medical devices in a biodegradable polymer-coated pouch containing rifampicin and/ or minocycline can inhibit biofilm formation by A. baumannii, E. coli, S. aureus and S. epidermis. 155 This type of device could also utilize EPIs in tandem with antibiotics to prevent biofilm formation on medical devices.
Conclusions
Efflux pumps have been widely studied in the context of antibiotic resistance, but it is now acknowledged that they also play physiological roles in bacteria, for example in biofilm formation. The studies reviewed here suggest that there may be multiple different roles for efflux pumps in biofilm formation. There are some common themes for the role of efflux pumps in biofilm formation, including efflux of osmoprotectants and sugars and up-regulation of efflux pumps under anaerobic conditions. The exact role of efflux pumps in the different stages of biofilm formation is not clear cut and remains to be investigated. For instance, it is unclear whether efflux pumps are necessary for initial attachment of cells, biofilm maturation or biofilm maintenance. This is likely to vary considerably between different species and individual strains of bacteria and with different substrata.
EPIs have been known for a while to be able to potentiate antibiotics in MDR pathogens. In addition, some EPIs have been reported to significantly decrease in vitro biofilm formation by several important pathogenic bacterial species. This combination of direct effects on biofilm formation and indirect improvements in antibiotic activity makes EPIs attractive from a development perspective. Although promising, no EPI has so far been approved for clinical use. The main reason for the failure to license current EPIs is due to toxicity as they require high concentrations to show efficacy.
Future perspectives
As it stands, our knowledge of the roles that efflux pumps play in biofilm formation is still in its infancy. The studies discussed in this review suggest that efflux pumps play various roles in biofilm formation in vitro. However, no study to date has investigated their roles using in vivo biofilm models. This makes it difficult to define their absolute roles in biofilm infections, where the conditions are vastly different. Furthermore, a different approach may be required to study the role of efflux pumps in biofilm formation since deleting an efflux pump may have pleiotropic effects, with other efflux pumps compensating for the loss. There is also certainly capacity to shuffle components of efflux pumps to produce hybrid systems that again may cloud any definitive phenotype. [156] [157] [158] Thus, targeted regulators of efflux pumps need to be considered, since they tend to have cleaner phenotypes compared with efflux gene mutants. 159, 160 The treatment of biofilm infections remains a significant challenge-hence different therapeutic strategies are necessary to inhibit biofilm formation. EPIs alone are not sufficient to eradicate biofilm formation, and therefore efforts need to be made to investigate the efficacy of combination therapy. This would involve the co-administration of EPIs with anti-biofilm agents, such as QS inhibitors, or employing EPIs to disrupt biofilm formation and then administering antibiotics to eradicate planktonic cells. In addition, some studies have reported that EPIs possess the ability to potentiate the anti-biofilm activity of photodynamic therapy. 161, 162 Another viable strategy for the development of EPIs and potential anti-biofilm agents could be to screen libraries of existing approved drugs. This has the advantage of reducing the risks associated with the development of new chemical entities, which can be very costly and time consuming. However, the EPI or anti-biofilm activity of the compound must be more potent than its original pharmacological activity. 163 For instance, the clinically approved drugs reserpine and verapamil both exhibit EPI activity; however, they are toxic at the concentrations required to inhibit efflux, 164 rendering them unsuitable for use as an EPI. However, if employed at lower concentrations in combination with other agents as described above, these drugs may find use as anti-biofilm agents.
An ideal EPI would be one that can inhibit a broad range of bacterial efflux pumps from different superfamilies, but not target mammalian efflux pumps. However, due to the diversity of efflux systems in bacteria, this would appear very difficult to achieve. Instead, designing narrow-spectrum EPIs could be the best approach to target specific types of efflux pumps that have been shown to play a greater role in biofilm formation than other types. For instance, a generic RND-targeted molecule could have the best prospects against A. baumannii and P. aeruginosa biofilms, whilst a generic MFS-targeted molecule could be effective against S. aureus biofilms. With the increasing prevalence of biofilm infections in clinical settings, there is a pressing need for new treatments. Our increasing knowledge of efflux pumps and their roles in biofilm Review formation will pave the way to developing effective treatments for biofilm infections in the future.
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